New Amsterdam Pharma
Robert Schildt is an experienced pharmaceutical executive currently serving as the Vice President of Go-to-Market & Omnichannel Strategy at NewAmsterdam Pharma Corporation. Previously, Robert held key marketing roles, including Head of Marketing for Nurtec ODT at Pfizer and Senior Director for Go-To-Market Innovation for the same product at Biohaven Pharmaceuticals. Robert's background also includes serving as the Director and Commercial Lead for Jardiance in Heart Failure at Boehringer Ingelheim, as well as Director of Global Marketing for Soliris at Alexion Pharmaceuticals, Inc.
This person is not in any teams
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.